Market Overview:
The global lysosomal storage diseases therapeutics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of lysosomal storage diseases, rising awareness about these diseases, and technological advancements in the field of lysosomal storage diseases therapeutics. However, high cost associated with treatment and lack of reimbursement policies are some factors that are likely to restrain the growth of this market during the forecast period. Based on type, the global lysosomal storage diseases therapeutics market is segmented into enzyme replacement therapy (ERT), stem cell therapy, substrate reduction therapy (SRT), and others. ERT dominates this market owing to its high efficacy in treating various types of lysosomal storage disorders.
Product Definition:
Lysosomal Storage Diseases Therapeutics is the term used to describe the therapies used to treat lysosomal storage diseases. These diseases are caused by defects in the lysosomes, which are organelles in cells that break down proteins and other molecules. When these organelles are defective, they cannot break down certain molecules, which leads to their accumulation in the cells. This can cause a variety of symptoms depending on the specific disease. There is no cure for most lysosomal storage diseases, but there are treatments available that can help manage symptoms and improve quality of life.
Enzyme Replacement Therapy:
Enzyme replacement therapy, ERT, is a treatment for lysosomal storage diseases (LSD). The disease causing agents are either genetic or due to environmental factors. In most cases the disease is caused by a defect in the enzyme that helps break down proteins.
Stem Cell Therapy:
Stem cell therapy is a new and emerging field of medicine that involves the use of stem cells to treat or cure fatal diseases. Stem cells are unique, self-renewing cells found in the human body. They possess the ability to replace any type of tissue or organ and can repair damaged areas within the body.
Application Insights:
The others application segment held the largest share of more than 50.0% in 2017. The other Lysosomal Storage Diseases Therapeutics applications include research studies, domestic facilities and abroad clinics & hospitals. Out of these, only hospitals accounted for a significant share as compared to clinics and hospitals in 2017 owing to the availability of advanced healthcare facilities with highly skilled personnel at home and abroad coupled with increasing awareness levels regarding these disorders is resulting in higher adoption rates for such therapies across the globe.
Regional Analysis:
North America Lysosomal Storage Diseases Therapeutics Market was valued at USD X million in 2017 and is expected to grow at a CAGR of XX% over the forecast period. The growth can be attributed to various factors such as favorable reimbursement policies, increasing awareness about lysosomal diseases, presence of key players in the region and funding for research & development activities pertaining to novel therapies for rare diseases.
Growth Factors:
- Increasing prevalence of lysosomal storage diseases (LSDs)
- Growing awareness about LSDs among people and healthcare professionals
- Rising demand for better treatment options for LSDs
- Technological advancements in the field of lysosomal storage diseases therapeutics
- increasing funding for research and development of new therapies for LSDs
Scope Of The Report
Report Attributes
Report Details
Report Title
Lysosomal Storage Diseases Therapeutics Market Research Report
By Type
Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others
By Application
Hospitals, Clinics, Others
By Companies
Takeda, Pfizer, Sanofi, BioMarin Pharmaceutical, Actelion Ltd, Raptor Pharmaceutical, Protalix BiOthersapeutics, Amicus Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Lysosomal Storage Diseases Therapeutics Market Report Segments:
The global Lysosomal Storage Diseases Therapeutics market is segmented on the basis of:
Types
Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- Pfizer
- Sanofi
- BioMarin Pharmaceutical
- Actelion Ltd
- Raptor Pharmaceutical
- Protalix BiOthersapeutics
- Amicus Therapeutics
Highlights of The Lysosomal Storage Diseases Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lysosomal Storage Diseases Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lysosomal storage diseases (LSDs) are a group of rare genetic disorders that cause problems with the body's ability to store and use energy. These disorders can affect any part of the body, but they are most commonly diagnosed in children and young adults. LSDs can cause serious health problems, including death, if not treated properly. There is currently no cure for LSDs, but there are treatments available that help improve the symptoms of these disorders. These treatments include medication and surgery. Some LSDs may also require special care during pregnancy or childbirth to ensure the baby does not develop the same disorder.
Some of the major companies in the lysosomal storage diseases therapeutics market are Takeda, Pfizer, Sanofi, BioMarin Pharmaceutical, Actelion Ltd, Raptor Pharmaceutical, Protalix BiOthersapeutics, Amicus Therapeutics.
The lysosomal storage diseases therapeutics market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lysosomal Storage Diseases Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lysosomal Storage Diseases Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lysosomal Storage Diseases Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lysosomal Storage Diseases Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lysosomal Storage Diseases Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Lysosomal Storage Diseases Therapeutics Market Size and Y-o-Y Growth
4.5.2 Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Enzyme Replacement Therapy
5.2.2 Stem Cell Therapy
5.2.3 Substrate Reduction Therapy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lysosomal Storage Diseases Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Enzyme Replacement Therapy
9.6.2 Stem Cell Therapy
9.6.3 Substrate Reduction Therapy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Enzyme Replacement Therapy
10.6.2 Stem Cell Therapy
10.6.3 Substrate Reduction Therapy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Enzyme Replacement Therapy
11.6.2 Stem Cell Therapy
11.6.3 Substrate Reduction Therapy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Enzyme Replacement Therapy
12.6.2 Stem Cell Therapy
12.6.3 Substrate Reduction Therapy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Enzyme Replacement Therapy
13.6.2 Stem Cell Therapy
13.6.3 Substrate Reduction Therapy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lysosomal Storage Diseases Therapeutics Market: Competitive Dashboard
14.2 Global Lysosomal Storage Diseases Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 Pfizer
14.3.3 Sanofi
14.3.4 BioMarin Pharmaceutical
14.3.5 Actelion Ltd
14.3.6 Raptor Pharmaceutical
14.3.7 Protalix BiOthersapeutics
14.3.8 Amicus Therapeutics
